Citations

Clear

237 citation(s) found for "Veronica, N".

Symptom burden in adolescents and young adults with cancer: A subgroup analysis of the enhanced, EHR-facilitated cancer symptom control (E2C2) trial.
Kour, Oudom, Ruddy, Kathryn J. , Pachman, Deirdre R. , Chlan, Linda L., Cobran, Ewan K. , Greenmyer, Jacob R. , Grzegorczyk, Veronica , Ehlers, Shawna L. , Storandt, Michael H. , Jin, Zhaohui , Kroenke, Kurt , Griffin, Joan M. , Austin, Jessica D. , Allen‐Rhoades, Wendy , Smith, Ashley Wilder , Mitchell, Sandra A , Shi, Qian , Cheville, Andrea

Mayo Clinic

Journal of Clinical Oncology | June 13, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 12065-12065

10.1200/jco.2024.42.16_suppl.12065 Get It

12065 Background: Incidence of cancer, including colorectal, breast, pancreas, kidney, and uterine cancer, is increasing in younger populations. Adolescents and young adults (AYA, defined as age 15-39) with cancer face unique challenges. This study aimed to characterize how symptom burden differs between AYA and non-AYA (aged 40+) patients with cancer. Methods: We performed a subgroup analysis of the E2C2 study, a cluster-randomized, pragmatic trial examining the effectiveness of routine symptom assessment and guideline-based management on patient-centered and healthcare utilization metrics during and following cancer treatment. Six symptoms [Sleep disturbance, Pain, Physical function impairment, Anxiety, Depression, and Energy deficit/fatigue (SPPADE)] were evaluated using 11-point numerical rating scales (NRS). Symptom severity was classified as mild (0-3), moderate (4-6), or severe (7-10). We conducted a subgroup analysis of symptom burden among AYA patients (defined as age 18-39 in this study), using their first-reported NRS scores. Results: The E2C2 cohort included 2,598 AYA patients and 38,061 non-AYA patients who completed >1 SPPADE NRS on at least one survey. AYA patients were more likely than non-AYA patients to report severe anxiety ( p<0.0001) and depression ( p<0.0001) (Table). Non-AYA patients were more likely to report severe pain ( p=0.02179), fatigue ( p=0.0022), and physical function limitations ( p<0.0001). Sociodemographic differences were also noted. A higher proportion of AYA patients held a bachelor’s degree or higher (38% vs 28%), were employed (73% vs 37%), and lived in an urban setting (67% vs 56%), compared to non-AYA patients. Non-AYA patients were more likely to have government insurance (63% vs 21%) and to be married (72% vs 59%). Conclusions: AYA patients with cancer were more likely to report severe depression and anxiety compared to their counterparts age 40 and above, underscoring the need for targeted and tailored psycho-oncology care for this population. [Table: see text]
Assessment of GFR in Patients with Cancer
Kitchlu, Abhijat , Silva, Verônica T. Costa e , Anand, Shuchi , Kala, Jaya , Abudayyeh, Ala , Inker, Lesley A. , Rosner, Mitchell H. , Karam, Sabine , Gudsoorkar, Prakash , Gupta, Shruti , Chen, Sheldon , Klomjit, Nattawat , Milanez, Tomaž, Motwani, Shveta S. , Khalid, Sheikh B. , Srinivasan, Vinay , Wanchoo, Rimda, Liu, Geoffrey , Geng, Yimin , Leung, Nelson , Motwani, Shveta S , Khalid, Sheikh B , Srinivasan, Vinay , Beumer, Jan Hendrik , Liu, Geoffrey , Orchanian-Cheff, Ani , Geng, Yimin , Herrmann, Sandra M , Gupta, Shruti , Kitchlu, Abhijat , Klomjit, Nattawat , Leung, Nelson , Tannir, Nizar , Herrmann, Sandra M.

Mayo Clinic

Clinical Journal of the American Society of Nephrology | June 7, 2024 | Volume: 19 | Issue: 8 | Pages: 1061-1072

10.2215/cjn.0000000000000508 | PMID 38848131 Get It

Accurate assessment of GFR is crucial to guiding drug eligibility, dosing of systemic therapy, and minimizing the risks of both undertreatment and toxicity in patients with cancer. Up to 32% of patients with cancer have baseline CKD, and both malignancy and treatment may cause kidney injury and subsequent CKD. To date, there has been lack of guidance to standardize approaches to GFR estimation in the cancer population. In this two-part statement from the American Society of Onco-Nephrology, we present key messages for estimation of GFR in patients with cancer, including the choice of GFR estimating equation, use of race and body surface area adjustment, and anticancer drug dose-adjustment in the setting of CKD. These key messages are based on a systematic review of studies assessing GFR estimating equations using serum creatinine and cystatin C in patients with cancer, against a measured GFR comparator. The preponderance of current data involving validated GFR estimating equations involves the CKD Epidemiology Collaboration (CKD-EPI) equations, with 2508 patients in whom CKD-EPI using serum creatinine and cystatin C was assessed (eight studies) and 15,349 in whom CKD-EPI with serum creatinine was assessed (22 studies). The former may have improved performance metrics and be less susceptible to shortfalls of eGFR using serum creatinine alone. Since included studies were moderate quality or lower, the American Society of Onco-Nephrology Position Committee rated the certainty of evidence as low. Additional studies are needed to assess the accuracy of other validated eGFR equations in patients with cancer. Given the importance of accurate and timely eGFR assessment, we advocate for the use of validated GFR estimating equations incorporating both serum creatinine and cystatin C in patients with cancer. Measurement of GFR via exogenous filtration markers should be considered in patients with cancer for whom eGFR results in borderline eligibility for therapies or clinical trials.
Primary outcomes of the enhanced, EHR-facilitated cancer symptom control (E2C2) cluster-randomized, stepped wedge, pragmatic trial.
Pachman, Deirdre R. , Grzegorczyk, Veronica , Chlan, Linda L., Tofthagen, Cindy , Ruddy, Kathryn J. , Tofthagen, Cindy S , Cheville, Andrea , Kroenke, Kurt , Herrin, Jeph , Mitchell, Sandra A , Griffin, Joan M. , Ridgeway, Jennifer L. , Austin, Jessica D. , Smith, Ashley Wilder

Mayo Clinic

Journal of Clinical Oncology | June 5, 2024 | Volume: 42 | Issue: 17_suppl | Pages: LBA12006-LBA12006

10.1200/jco.2024.42.17_suppl.lba12006 Get It

LBA12006 Background: Symptom burden and functional decline are prevalent, inconsistently treated, and associated with adverse health outcomes in patients with cancer. Symptom monitoring with electronic patient-reported outcome measures (ePROMs) has yielded mixed results due, in part, to care teams’ variable bandwidth and resourcing for symptom management. The collaborative care model (CCM) offers a validated means to address these issues and potentially improve clinical and health services outcomes. Capturing ePROMS through the electronic health record (EHR) for use in CCM delivery provides a potentially scalable approach to manage symptoms at the population level. Methods: E2C2 is a cluster-randomized, population-level, stepped wedge pragmatic trial that compares a bundled, EHR-facilitated, CCM-based intervention to improve control of SPPADE symptoms (Sleep interference, Pain, impaired Physical function, Anxiety, Depression, and Energy deficit/fatigue) with usual care. All patients, regardless of cancer type or stage, treated in the medical oncology clinics of a multi-state health system, were assigned to one of fifteen clusters. Control and intervention conditions monitored SPPADE symptoms with Epic EHR administered 11-point numerical rating scales (NRSs). Moderate and severe symptoms were defined as 4-6/10 and >7/10, respectively. The intervention added EHR clinician decision support; automated delivery of symptom self-management information; and options to address severe symptoms with a dedicated symptom care manager. The primary outcome was post-baseline SPPADE scores assessed using multivariate regression of six cluster-period mean SPPADE symptom scores against E2C2 exposure, fixed cluster and secular time effects. Results: From March 2019 to January 2023, 50,559 patients were assigned to E2C2 clusters and 40,295 completed at least one ePROM. At first assessment, participants’ mean age was 63.3 years; 58% were female; 26% were rural, and the prevalences of moderate or worse symptoms were fatigue 42%, impaired function 34%, sleep disturbance 34%, anxiety 27%, pain 26%, and depression 23%. The intervention significantly reduced mean composite SPPADE symptom scores, p <0.001, among all patients, as well as those with >1 moderate or worse symptom. All mean symptom scores were lower in the intervention group, with the largest effects detected among patients with fatigue -0.2 (-0.4, -0.07), anxiety -0.14 (-0.2, -0.03), and depression -0.1 (-0.2, -0.002). Conclusions: In this large cluster-randomized trial, an EHR-facilitated, bundled intervention that scaled CCM-based surveillance and management of SPPADE symptoms significantly reduced population-level symptom burden, particularly for fatigue, anxiety, and depression. This study provides real world evidence and the foundation for future national efforts aimed at controlling symptoms in patients with cancer. Clinical trial information: NCT03892967 .
Recommendations for the assessment of glomerular filtration rate in patients with cancer: A position statement and systematic review on behalf of the American Society of Onco-Nephrology (ASON).
Abudayyeh, Ala , Khalid, Sheikh B. , Khalid, Sheikh B , Kitchlu, Abhijat , Silva, Verônica T. Costa e , Anand, Shuchi , Kala, Jaya , Inker, Lesley A. , Liu, Geoffrey , Leung, Nelson , Herrmann, Sandra M.

Mayo Clinic

Journal of Clinical Oncology | June 4, 2024 | Volume: 42 | Issue: 16_suppl | Pages: e24143-e24143

10.1200/jco.2024.42.16_suppl.e24143 Get It

e24143 Background: Accurate assessment of glomerular filtration rate (GFR) is crucial to guiding drug eligibility, dose-adjusting systemic therapy, and minimizing the risks of both undertreatment and toxicity in patients with cancer. To date, there has been a lack of guidance to standardize approaches to GFR estimation in the cancer population based on the available evidence. We aim to present data on the first systematic review (SR) of GFR estimating equations in patients with cancer. Methods: We conducted a SR on behalf of the American Society of Onco-Nephrology (ASON) on the accuracy of equations to estimate GFR in adult patients with cancer, in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We required that studies use a reference methodology as comparator involving measured GFR via urinary or plasma clearance of an exogenous filtration marker or carboplatin. Two search strategies focusing on studies using serum creatinine (Cr) and cystatin C (Cys) were developed. Risk of bias and quality assessment was performed for all studies. Results: A total of 39 studies (21,949 patients in total, 19,025 with solid cancers) were included. Studies assessing populations in Europe were most frequent (50%), followed by Asia (27%) and the remaining from Australia/New Zealand and North and South America. Risk of bias and quality assessment allocated 15 studies (38%) as low or very low quality, and 24 (62%) as low-moderate or moderate quality. The most commonly assessed GFR estimating equations included Cockroft-Gault (32 studies), Modification of Diet Renal Disease (MDRD) (24 studies), Chronic Kidney Disese Epidemiology Collaboration Study (CKD-EPI)Cr (22 studies), Wright (13 studies), CKD-EPICys (8 studies), CKD-EPICr-Cys (8 studies), and Jeliffe (8 studies). Given the importance of accurate and timely eGFR assessment and the evidence supporting the performance (i.e., accuracy) of the CKD-EPI incorporating both Cr and Cys, we suggest the use of this equation in patients with cancer (grade 2C). Where Cys is unavailable, CKD-EPICr is the next preferred equation given the supporting data for its performance and widespread availability. Since included studies were moderate quality or lower, the ASON rated the certainty of evidence as low. Also, additional data on clinical outcomes related to the selection of eGFR equations is needed. We suggest measurement of GFR via an exogenous filtration marker in patients with cancer for whom eGFR results in borderline eligibility for therapies or clinical trials (ungraded). Conclusions: Based on the results of this SR, we suggest use of contemporary methods for estimation of GFR (CKD-EPICr-Cys and CKD-EPICr-Cr) and avoidance of older and less accurate formulae such as Cockcroft-Gault.
SPPADE symptom prevalence and severity in a diverse sample of patients living with metastatic cancers.
Pachman, Deirdre R. , Ruddy, Kathryn J. , Grzegorczyk, Veronica , Chlan, Linda L., Leventakos, Konstantinos , Strand, Jacob J. , Kroenke, Kurt , Griffin, Joan M. , Ridgeway, Jennifer L. , Tofthagen, Cindy , Austin, Jessica D. , Smith, Ashley Wilder , Mitchell, Sandra A , Herrin, Jeph , Cheville, Andrea

Mayo Clinic

Journal of Clinical Oncology | June 3, 2024 | Volume: 42 | Issue: 16_suppl | Pages: 11108-11108

10.1200/jco.2024.42.16_suppl.11108 Get It

11108 Background: Advances in cancer treatment have led to a growing population of patients living with metastatic cancer. Symptom burden for these patients is understudied. Our objective is to report the prevalence and severity of SPPADE symptoms (sleep disturbance, pain, physical function impairment, anxiety, depression, and low energy /fatigue) in a large cohort of patients with metastatic cancer. Methods: These data are drawn from the Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) stepped wedge pragmatic trial evaluating a symptom management intervention for cancer patients (NCT03892967). This analysis was limited to those identified with metastatic disease using ICD- codes and a natural language processing algorithm prior to or within 30 days of their baseline symptom survey. Symptom severity was measured on a 0-10 scale with scores of 1-3 categorized as “mild”, 4-6 as “moderate”, and ≥7 as “severe.” A SPPADE composite score was calculated by summing six individual symptom scores and is an indicator of total symptom burden. We report descriptive statistics for each symptom by severity category. We also test for differences in SPPADE composite score by race, disability status, employment status, education and cancer type using Kruskal-Wallis tests. Results: 12,824 patients with metastatic disease completed a survey between March 2019 and January 2023. Discretized score distributions for the SPPADE symptoms are reported in the Table. The SPPADE composite mean score for the cohort was 17.6 (SD +/- 12.0). Significant differences were found in total symptom burden by sociodemographic and clinical characteristics ( p<0.01): Higher total symptom burden (Mean [SD])was experienced by individuals who were American Indian/Alaska Native (AI/AN) (23.8[13.5]) or African American (AA) (20.5[14.7]), disabled (24.0[12.8]) or unemployed (21.1[13.0]), and had a high school education (20.0[13.3]) or less than high school education (18.5[12.4]). There were also statistically significant differences ( p<0.01) in symptom burden across cancer types, with patients with metastatic lung cancer reporting the highest symptom burden (20.0[12.2]) and those with metastatic melanoma reporting the lowest (14.7[11.4]). Conclusions: SPPADE symptoms are common in patients with metastatic cancer, especially fatigue, sleep disturbance, and physical function impairment. Symptom burden is especially high in AI/AN, AA, disabled/unemployed, and less educated patients. Further research is needed to tailor symptom interventions among those living with metastatic disease. [Table: see text]
Genetic Prevalence Estimates for All Types of Primary Hyperoxaluria
Rumsby, Gill , Glover, Michelle, Mandrile, Giorgia , Sciannameo, Veronica , Harris, Peter C. , Lieske, John C.

Mayo Clinic

Journal of the American Society of Nephrology | May 18, 2024 | Volume: 34 | Issue: 11S | Pages: 565-566

10.1681/asn.20233411s1565e Get It

Abstract PO2-12-09: Insomnia, Pain, Anxiety, Distress, Fatigue, and Functional Impairment in Patients with Breast Cancer
Ruddy, Kathryn J. , Grzegorczyk, Veronica , Pachman, Deirdre R. , Smith, Deanne, O’Sullivan, Ciara C. , Ehlers, Shawna L. , Rahman, Parvez, Mitchell, Sandra A , Liu, Bolun , Herrin, Jeph , Cheville, Andrea

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: PO2-12-09-PO2-12-09

10.1158/1538-7445.sabcs23-po2-12-09 Get It

Abstract Background: SPPADE symptoms (Sleep disturbance, Pain, Physical function impairment, Anxiety, Depression/distress, and Energy deficits/fatigue) may result from cancer and its treatment. The aim of this analysis was to characterize SPPADE symptoms in patients with breast cancer. Methods. SPPADE data were drawn from the Enhanced, EHR-facilitated Cancer Symptom Control (E2C2) study, a stepped-wedge pragmatic cluster-randomized trial designed to evaluate a symptom management intervention in routine practice (NCT03892967). Symptom severity was measured on a 0-10 scale via a survey administered by patient portal, in-clinic tablet, or interactive voice response system (by phone) prior to, during, or soon after an outpatient oncology encounter. Scores of 4-6 were categorized as “moderate” and ≥7 as “severe.” In this analysis, only the data from each patient’s initial survey were included. Results. A total of 9,651 patients with breast cancer completed an initial E2C2 survey between March 2019 and January 2023. The proportion of patients with moderate or severe SPPADE symptoms were as follows: 22% moderate and 10% severe for insomnia; 18% moderate and 7% severe for pain; 17% moderate and 7% severe for anxiety; 15% moderate and 5% severe for emotional distress; 25% moderate and 12% severe for fatigue; and 22% moderate and 8% severe for impaired physical function. Table 1 presents score means and standard deviations by demographic subgroup. Conclusions. SPPADE symptoms are common in patients with breast cancer. These observations warrant routine implementation of symptom surveillance and management in breast oncology. Funding acknowledgement: The Improving the Management of symPtoms during And following Cancer Treatment (IMPACT) Consortium is a Cancer Moonshot Research Initiative under the authorization of the 2016 United States 21st Century Cures Act. This research was supported by the National Cancer Institute of the NIH, UM1CA233033 (Mayo Clinic, Rochester, MN). Insomnia, Pain, Anxiety, Distress, Fatigue, and Functional Impairment in Patients with Breast Cancer Citation Format: Kathryn Ruddy, Veronica Grzegorczyk, Deirdre Pachman, Sandra Mitchell, Bolun Liu, Deanne Smith, Ciara O'Sullivan, Shawna Ehlers, Jeph Herrin, Parvez Rahman, Andrea Cheville. Insomnia, Pain, Anxiety, Distress, Fatigue, and Functional Impairment in Patients with Breast Cancer [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-12-09.
Cardiac Effort Is Less Variable Than Six-minute Walk Distance, Correlates With Hemodynamics and Is Consistent With REVEAL 2.0 Risk Score in a Sub-study of the TORREY Phase 2 PAH Trial
Lachant, Daniel , Osterhout, Robin , Chakinala, Murali M. , Franco, Verónica , McConnell, J.W. , Rahaghi, Franck , Sood, Namita , Spikes, Leslie , Benza, R.L., Channick, Richard N. , McLaughlin, Vallerie V. , Zamanian, R.T., Roscigno, R.F., Mottola, David, Parsley, E., Cravets, Matt , Bruey, Jean Marie, Zisman, Lawrence S. , White, R.J., Osterhout, Robin E. , Sahay, Sandeep , Channick, Richard N. , Chin, Kelly M , Frantz, Robert P. , Ghofrani, Hossein Ardeschir , Hemnes, Anna R. , Howard, Luke , McLaughlin, Vallerie V. , Sitbon, Olivier , White, R. James

Mayo Clinic

D109. NOW WE GOT BAD BLOOD: RSF/PC JOINT SESSION ON PULMONARY VASCULAR DISEASE | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A7475-A7475

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a7475 Get It

Mixed histiocytic neoplasms: A multicentre series revealing diverse somatic mutations and responses to targeted therapy
Friedman, Joshua, Yabe, Mariko , Petrova‐Drus, Kseniya , Pulitzer, Melissa , Busam, Klaus J. , Rampal, Raajit K. , Ulaner, Gary A. , Reddy, Ryan , Yeh, Randy , Rotemberg, Veronica , Hershkovitz‐Rokah, Oshrat , Shpilberg, Ofer , Abeykoon, Jithma P. , Fidai, Shiraz , Gannamani, Vedavyas, Zia, Maryam, Panageas, Katherine S. , Rosenblum, Marc K. , Durham, Benjamin H. , Reiner, Anne S , Mazor, Roei D , Hershkovitz-Rokah, Oshrat , Goyal, Guarav , Abeykoon, Jithma P , Diamond, Eli L , Ulaner, Gary , Reiner, Anne S. , Doǧan, Ahmet , Francis, Jasmine H. , Hatzoglou, Vaios , Lacouture, Mario E. , Mazor, Roei David , Goyal, Gaurav , Go, Ronald S. , Rech, Karen L. , Morlote, Diana M. , Abdel‐Wahab, Omar , Diamond, Eli L.

Mayo Clinic

British Journal of Haematology | April 13, 2024 | Volume: 205 | Issue: 1 | Pages: 127-137

10.1111/bjh.19462 | PMID 38613141 Get It

Summary Histiocytic neoplasms are diverse clonal haematopoietic disorders, and clinical disease is mediated by tumorous infiltration as well as uncontrolled systemic inflammation. Individual subtypes include Langerhans cell histiocytosis (LCH), Rosai–Dorfman–Destombes disease (RDD) and Erdheim–Chester disease (ECD), and these have been characterized with respect to clinical phenotypes, driver mutations and treatment paradigms. Less is known about patients with mixed histiocytic neoplasms (MXH), that is two or more coexisting disorders. This international collaboration examined patients with biopsy‐proven MXH with respect to component disease subtypes, oncogenic driver mutations and responses to conventional (chemotherapeutic or immunosuppressive) versus targeted (BRAF or MEK inhibitor) therapies. Twenty‐seven patients were studied with ECD/LCH (19/27), ECD/RDD (6/27), RDD/LCH (1/27) and ECD/RDD/LCH (1/27). Mutations previously undescribed in MXH were identified, including KRAS, MAP2K2, MAPK3, non‐V600‐BRAF, RAF1 and a BICD2‐BRAF fusion. A repeated‐measure generalized estimating equation demonstrated that targeted treatment was statistically significantly (1) more likely to result in a complete response (CR), partial response (PR) or stable disease (SD) (odds ratio [OR]: 17.34, 95% CI: 2.19–137.00, p = 0.007), and (2) less likely to result in progression (OR: 0.08, 95% CI: 0.03–0.23, p < 0.0001). Histiocytic neoplasms represent an entity with underappreciated clinical and molecular diversity, poor responsiveness to conventional therapy and exquisite sensitivity to targeted therapy.